Discover investment opportunities in Stocks Under $50 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Under $50 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Under $50 using our Smart AI Filter.
10 stocks found for "Stocks Under $50"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.06 | ±80.2% | -2.8 | 0.00% | |||
1.73 | ±64.4% | 28.8 | 0.00% | |||
0.31 | ±23.4% | 12.7 | 3.92% | |||
1.75 | ±96.8% | 75.3 | 0.00% | |||
1.06 | ±59.4% | 23.2 | 0.00% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.79 | ±28.3% | 9.6 | 3.25% | |||
0.74 | ±35.1% | 6.3 | 1.20% | |||
0.23 | ±21.9% | 9.2 | 6.32% | |||
0.61 | ±38.9% | 6.7 | 5.08% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How has Ford's (F) stock performance been impacted by the shift towards electric vehicles?
A: Ford's stock performance has been influenced by its strategic investments in electric vehicles (EVs), including the launch of models like the Mustang Mach-E and F-150 Lightning. The company's commitment to EVs has attracted investor interest, but competition and supply chain challenges pose risks.
Q: What dividend yield can investors expect from Pfizer (PFE) compared to other pharmaceuticals?
A: Pfizer is known for offering relatively high dividend yields compared to its peers in the pharmaceutical industry. However, investors should assess payout ratios and pharma-specific risks that may impact future dividend sustainability.
Q: How does AT&T's (T) debt impact its stock valuation?
A: AT&T traditionally carries a high debt level due to acquisitions, impacting its stock valuation. Investors may consider debt reduction strategies and cash flow sufficiency as critical factors for financial stability and continued dividend payouts.
Q: Does Verizon (VZ) provide competitive growth potential in the telecom sector?
A: Verizon offers moderate growth potential, driven by 5G network expansion and customer retention. Growth may be limited by saturated markets and regulatory pressures, which investors should consider when assessing its long-term potential.
Q: Are Kraft Heinz (KHC) stocks affected by changing consumer preferences?
A: Kraft Heinz faces challenges from evolving consumer preferences toward healthier foods, impacting demand for its products. Strategic shifts towards organic and healthier options may help mitigate these risks.
Q: What effect does Walgreens Boots Alliance’s (WBA) retail strategy have on its growth prospects?
A: WBA's growth prospects are influenced by its retail and healthcare synergy strategy, including partnerships and expanding healthcare services. However, the competitive retail environment and healthcare regulation changes may pose growth challenges.
In late August, the U.S. government agreed to take roughly a 10 percent equity stake in Intel, converting about $8.9 billion of previously committed CHIPS and Secure Enclave funds into shares. This is an unprecedented move that effectively swaps subsidies for ownership.
Read moreThe mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read more